ArticleDiagnostics (Basel, Switzerland)2025
Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.
Article in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive Supranuclear Palsy (PSP) is an atypical Parkinsonism, pathologically described as a four-repeat tauopathy. The contemporary criteria for diagnosis of PSP indicate akinesia, oculomotor dysfunction, postural instability, and language/cognitive impairment as core symptoms. Among these features, the first two are linked to PSP-Parkinsonism predominant (PSP-P). PSP-P is the second most common subtype of PSP, following PSP-Richardson's syndrome (PSP-RS), and is associated with a more gradual deterioration, beneficial course, and longer life expectancy after diagnosis. It is also problematic in terms of clinical evaluation, as this entity may overlap with Parkinson's disease (PD) in early stages and with other atypical Parkinsonisms in more advanced stages. The evolution in understanding PSP and the possible progress in care and therapy of the disease leads to the necessity of finding optimal examination methods with sufficient sensitivity and specificity. In this context, PSP-P seems a crucial point. The goal of this narrative review is to provide an overview of the possibilities provided by Magnetic Resonance Imaging (MRI) assessments in terms of PSP-P and analyze their strengths and weaknesses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.